More fit KL-VS heterozygotes have more favorable AD-relevant biomarker profiles.
Mackenzie Jarchow, Ira Driscoll, Brianne M Breidenbach, Noah Cook, Catherine L Gallagher, Sterling C Johnson, Sanjay Asthana, Bruce P Hermann, Mark A Sager, Kaj Blennow and 7 more
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Mackenzie JarchowWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.ORCID https://orcid.org/0009-0004-6677-5447
Ira DriscollWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.ORCID https://orcid.org/0000-0002-1737-3343
Brianne M BreidenbachWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Noah CookWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Catherine L GallagherGeriatric Research Education and Clinical Center William S. Middleton VA Hospital Madison Wisconsin USA.
Sterling C JohnsonWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Sanjay AsthanaWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Bruce P HermannWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Mark A SagerWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Kaj BlennowDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden.
Henrik ZetterbergWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Cynthia M CarlssonWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Clara Quijano-RubioRoche Diagnostics International Ltd Rotkreuz Switzerland.
Dane B CookResearch Service William S. Middleton VA Hospital Madison Wisconsin USA.
Dena B DubalDepartment of Neurology and Weill Institute for Neurosciences University of California San Francisco California USA.
Ozioma C OkonkwoWisconsin Alzheimer's Disease Research Center Department of Medicine School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Funding
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
The Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0M
African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAREY E GLEASON · 2016 to 2026
$15.3M
Longitudinal Investigation of Cardiorespiratory Fitness and AD Biomarkers in an At-Risk CohortR01AG062167 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI OKONKWO, OZIOMA C · 2019 to 2023
$4.5M
KLOTHO and Resilience to Synaptic Dysfunction in Preclinical ADR01AG077507 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Ira Frahmand, Ozioma C Okonkwo · 2023 to 2026
$3.1M
Sleep and Aerobic Fitness as Midlife Modifiers of Later Life Cognitive Decline and Alzheimer's Disease Biomarkers in the Wisconsin Sleep CohortR01AG085592 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Ozioma C Okonkwo, PAUL E PEPPARD · 2024 to 2026
$2.3M
Klotho and Neurodegenerative DiseaseR01NS092918 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBAL, DENA BOU · 2016 to 2020
introductionAlthough hallmarked by β-amyloid plaques (Aβ) and neurofibrillary tangles (tau), Alzheimer's disease (AD) is a multifactorial disorder that involves neuroinflammation, neurodegeneration, and synaptic dysfunction. AD-associated biomolecular changes seem to be attenuated in carriers of the functionally advantageous variant of the
methodsThe cohort, enriched for AD risk, consisted of cognitively unimpaired adults (
resultsThe interaction between VO
conclusionsWe report a synergistic relationship between KL-VS Highlights:
Indexed as
AD riskAlzheimer's diseasecerebrospinal fluid biomarkersexerciseprotective factorsresilience
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
More fit KL-VS heterozygotes have more favorable AD-relevant biomarker profiles. · full record | OpenQuestion